MINNEAPOLIS, March 02, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the following upcoming investor conferences:
The 33rd Oppenheimer Annual Healthcare Conference, which is being held virtually from March 13th-15th.
The Sidoti Small-Cap Conference, which is being held virtually from March 22nd-23rd.
Live audio webcasts of the presentations will be accessible under the “Events & Webcasts” section of the Company's investor relations website at http://investors.tactilemedical.com. Archives of the webcasts will be available for replay following each conference.
About Tactile Medical
Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. The company collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.
Last Trade: | US$10.28 |
Daily Change: | 0.39 3.94 |
Daily Volume: | 274,399 |
Market Cap: | US$246.720M |
March 05, 2025 February 18, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load